Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Dokumenter

Morten Møller Poulsen, Karen Fjeldborg, Marie Juul Ornstrup, Thomas Nordstrøm Kjær, Mark Klitgaard Nøhr, Steen Bønløkke Pedersen

Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

OriginalsprogEngelsk
TidsskriftB B A - Molecular Basis of Disease
Vol/bind1852
Udgave nummer6
Sider (fra-til)1124-1136
Antal sider13
ISSN0925-4439
DOI
StatusUdgivet - 2015
Eksternt udgivetJa

ID: 195591641